Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

J. Olson, Daniel; Eroglu, Zeynep; Brockstein, Bruce; Poklepovic, Andrew; Bajaj, Madhuri; Babu, Sunil; Hallmeyer, Sigrun; R. Velasco, Mario; Lutzky, Jose; F. Higgs, Emily; Bao, Riyue; Carll, Timothy; Labadie, Brian; Krausz, Thomas; Zha, Yuanyuan; Karrison, Theodore; K. Sondak, Vernon; F. Gajewski, Thomas; I. Khushalani, Nikhil; J. Luke, Jason

doi:10.1200/jco.21.00079

Public

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Published in Journal of Clinical Oncology • May 4, 2021

Authors:

Daniel J. Olson

Zeynep Eroglu

Bruce Brockstein

Abstract

PURPOSE: Combination of antiprogrammed cell death protein-1 (PD-1) plus anti-cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and programmed death ligand-1 (PD-L1) antibody progressi...

Subject

Ipilimumab

Pembrolizumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!